Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4'-hydroxylation phenotype status

Clinical Pharmacology and Therapeutics

Volumn 61, Issue 5, 1997, Pages 574-582

  Sohn, Dong Ryul ^a   Kwon, Jun Tack ^b   Kim, Hyung Kee ^b   Ishizaki, Takashi ^b  

^a Soonchunhyang University College of Medicine   (South Korea)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DRUG METABOLITE; LANSOPRAZOLE; MEPHENYTOIN; OXYGENASE; PRODRUG; PROTON PUMP INHIBITOR; SULFONE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG CAPSULE; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG URINE LEVEL; ENTERIC COATED TABLET; GENETIC POLYMORPHISM; HUMAN; HUMAN EXPERIMENT; KOREA; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHENOTYPE; PRIORITY JOURNAL;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADMINISTRATION, ORAL; ADULT; ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INHIBITORS; H(+)-K(+)-EXCHANGING ATPASE; HUMANS; HYDROXYLATION; KOREA; MALE; MEPHENYTOIN; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; PHENOTYPE; POLYMORPHISM, GENETIC;

EID: 0030938161     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(97)90137-5     Document Type: Article

References (32)

1. Brøsen K. Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics. Clin Pharmacokinet 1990;18:220-39.
2. Brockmöller J, Roots I. Assessment of liver metabolic function: clinical implications. Clin Pharmacokinet 1994;27:216-48.
3. Kupfer A, Preisig R. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 1984;26:753-9.
4. Wedlund PJ, Aslanian WS, McAllister CB, Wilkinson GR, Branch RA. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther 1984;36:773-80.
5. Wrighton SA, Stevens JC, Becker GW, Vanden-Branden M. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch Biochem Biophys 1993;306:240-5.
6. Goldstein JA, Palette MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 1994;33:1743-52.
7. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenvtoin in humans. J Biol Chem 1994;269:15419-22.
8. Wilkinson GR, Guengerich FP, Branch RA. Genetic polymorphism of 5-mephenytoin hydroxylation. Pharmacol Ther 1989;43:53-76.
9. Jurima M, Inaba T, Kadar D, Kalow W. Genetic polymorphism of mephenytoin p(4′)-hydroxylation: difference between Orientals and Caucasians. Br J Clin Pharmacol 1985;19:483-7.
10. Horai Y, Nakano M, Ishizaki T, Ishikawa K, Zhou HH, Zhou BI, et al. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 1989;46:198-207.
11. Sohn DR, Kusaka M, Ishizaki T, Shin SG, Jang IJ, Shin JG, et al. Incidence of 5-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. Clin Pharmacol Ther 1992;52:160-9.
12. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, et al. Interethnic differ-ences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985; 38:402-8.
13. Alván G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990;39:533-7.
14. Ward SA, Walle T, Walle UK, Wilkinson GR, Branch RA. Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin Pharmacol Ther 1989;45:72-9.
15. Koyama E, Sohn DR, Shin SG, Chiba K, Shin JG, Kim YH, et al. Metabolic disposition of imipramine in Orientai subjects: relation to metoprolol α-hydroxylation and S-mephenytoin 4′-hydroxylation phenotypes. J Pharmacol Exp Ther 1994;271:860-7.
16. Bertilsson L, Henthorn TK, Sanz E, Tybring G, Säwe J, Villén T. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin Pharmacol Ther 1989;45:348-55.
17. Sohn DR, Kobayashi K, Chiba K, Lee KH, Shin SG, Ishizaki T. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation recruited from an Oriental population. J Pharmacol Exp Ther 1992;262: 1195-202.
18. Andersson T, Miners JO, Veronese ME, Tassaneeyakul WI, Tassaneeyakul WO, Meyer UA, et al. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 1993;36:521-30.
19. Chiba K, Kobayashi K, Manabe K, Tani M, Kamataki T, Ishizaki T. Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4′-hydroxylation. J Pharmacol Exp Ther 1993;266:52-9.
20. Satoh H, Inatomi N, Nagaya H, Inada I, Nohara A, Nakamura N. Antisecretory activities of a novel proton pump inhibitor G-1749 in dogs and rats. J Pharmacol Exp Ther 1989;248:806-15.
21. +)-adenosine triphosphatase by proton pump inhibitor AG-1749. J Pharmacol Exp Ther 1988;248:799-805.
22. Barradell LB, Faukds D, McTavish D. Lansoprazole: a review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acidrelated disorders. Drugs 1992;44:225-50.
23. Hawkey CJ, Long RG, Bardham KD, Wormsley KG, Cochran KM, Christian J, et al. Improved symptom relief and duodenal ulcer healing with lansoprazole, a new proton pump inhibitor, compared with ranitidine. Gut 1993;34:1458-62.
24. Delhotal Landes B, Petite JP, Flouvat B. Clinical pharmacokinetics of lansoprazole. Clin Pharmacokinet 1995;28:458-70.
25. Hussein Z, Granneman GR, Mukherjee D, Samara E, Hogan DL, Koss MA, et al. Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole. Br J Clin Pharmacol 1993;36:391-8.
26. Tucker GT. The interaction of proton pump inhibitors with cytochromes P450. Aliment Pharmacol Ther 1994;8:33-8.
27. Andersson T, Regårdh CG, Lou YC, Zhang Y, Dahl ML, Bertilsson L. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 1992;2:25-31.
28. m2 in exon 4, in Japanese subjects. Clin Pharmacol Ther 1996;59:647-53.
29. Karol MD, Granneman GR, Alexander K. Determination of lansoprazole and five metabolites in plasma by high-performance liquid chromatography. J Chromatogr B 1995;668:182-6.
30. Delhotal-Landes B, Flouvat B, Duchier J, Molinie P, Dellatolas F, Lemaire M. Pharmacokinetics of lansoprazole in patients with renal or liver diseases of varying severity. Eur J Clin Pharmacol 1993;45:367-71.
31. Pichard L, Curi-Pedrosa R, Bonfils C, Jacqz-Aigrain E, Domergue J, Joyeux H, et al. Oxidative metabolism of lansoprazole by human liver cytochromes P450. Mol Pharmacol 1995;47:410-8.
32. Pearce RE, Rodrigues AD, Goldstein JA, Parkinson A. Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther 1996;277:805-16.